12.01.2016 • News

ChemChina Buys KraussMaffei for €925 Million

A consortium of investors surrounding China National Chemical Corp, also known as ChemChina – China's biggest chemical producer and rival to Monsanto in the race to swallow up Swiss agrochemicals giant Syngenta – is paying €925 million (around $1 billion) to acquire German plastics and rubber machinery manufacturer KraussMaffei from Canadian private equity investor Onex.

Onex acquired the business in 2012 for €568 million from Madison Capital Partners in a bidding war that included Asian investors. In addition to ChemChina, another Chinese machinery manufacturer, Haitian, had shown interest in the business, as well as Japan's Sumitomo and US machinery maker Milacron.

The KraussMaffei takeover, expected to close in the first half of this year, will be the biggest-ever by a Chinese company in Germany. Investors involved in the financing include private-equity firm AGIC Capital and Chinese state fund Guoxin International Investment Corp.

In addition to the KraussMaffei machinery brand, the German company, which was acquired by Mannesmann in 1989 with the combined assets split up and rebranded as KraussMaffei, also owns the brands Netstal and Berstorff.

ChemChina said it would retain KraussMaffei’s headquarters at Munich. 2,800 of the machinery maker’s 4,500 employees are based in Germany.

One of China's most active investors abroad, the state-owned company has bought businesses in France, Britain and Israel, and agreed last year to pay $7.7 billion for Italian tire maker Pirelli.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.